Reporting from the ESMO Virtual Congress 2020, Maria De Santis comments on promising therapeutic options and practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).
She emphasises the importance of testing CRPC patients for genomic alterations (BRCA1, BRCA2 or ATM) as soon as the cancer metastasises, to identify those who could benefit from targeted treatment options.
Abstracts:
- LBA4 - IPATential150: efficacy and safety from the Phase III study of ipatasertib plus abiraterone-prednisone (AP) vs placebo plus AP in metastatic castrate-resistant prostate cancer (mCRPC)
- 610O - Final overall survival (OS) analysis of PROfound: olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
This video was supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson